{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:35:07Z","timestamp":1788240907627,"version":"build-2803163510"},"reference-count":121,"publisher":"Bentham Science Publishers Ltd.","issue":"11","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Psoriasis has been considered as a chronic inflammatory skin disease which leads to the\ndysfunction of immune systems. According to the World Psoriasis Day consortium, psoriasis affects\naround 125 million individuals globally or about 2% to 3% of the overall population. Most of the\nconventional drug delivery systems primarily attempt to relieve symptoms of psoriasis and are ineffective\nin providing targeted action and higher bioavailability because of the drug's short half-life\nand instability, as well as they lack safety and efficacy. The shortcomings of conventional drug\ndelivery systems give rise to the development of novel drug delivery systems which includes\nliposomes, transferosomes, ethosomes, niosomes, emulsomes, dendrimers, hydrogel, nanoparticles,\netc. These novel formulations may enhance the therapeutic effects by changing physiological and\npharmacokinetic parameters. Several research reports suggest that these novel drug delivery systems\nmay enhance therapeutic effects which can be used as a promising approach for the treatment of\npsoriasis. The liposomes based drug delivery system have been considered as most promising vehicles\nfor enhancing therapeutic potentials of drugs into or through the skin upon topical application.\nLiposomes have small unilamellar vesicles which may enhance the penetration ability through stratum\ncorneum layer of skin. Therefore, present review article highlights on the different aspects of\nthe liposomes as potential drug delivery system for the treatment of psoriasis.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201024666221213144228","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T14:06:03Z","timestamp":1671026763000},"page":"1383-1396","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Liposome Based Drug Delivery for the Management of Psoriasis -\nA Comprehensive Review"],"prefix":"10.2174","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9429-2857","authenticated-orcid":true,"given":"Shiv","family":"Bahadur","sequence":"first","affiliation":[{"name":"Institute of Pharmaceutical Research, GLA University, Mathura - 281406, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Sharma","sequence":"additional","affiliation":[{"name":"School of Management and Business\nStudies, Jamia Hamdard, New Delhi - 110062, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0168-3659(01)00299-1","volume":"73","author":"Torchilin V.P.","year":"2001","unstructured":"Torchilin V.P.; Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2001,73(2-3),137-172","journal-title":"J Control Release"},{"key":"ref=2","unstructured":"The National Psoriasis FoundationAvailable from:  [Accessed March 23, 2022]."},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jconrel.2016.07.003","volume":"239","author":"Sala M.","year":"2016","unstructured":"Sala M.; Elaissari A.; Fessi H.; Advances in psoriasis physiopathology and treatments: Up to date of mechanistic insights and perspec-tives of novel therapies based on Innovative Skin Drug Delivery Systems (ISDDS). J Control Release 2016,239,182-202","journal-title":"J Control Release"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.biopha.2018.07.156","volume":"107","author":"Pradhan M.","year":"2018","unstructured":"Pradhan M.; Alexander A.; Singh M.R.; Singh D.; Saraf S.; Saraf S.; Ajazuddin, Understanding the prospective of nano-formulations towards the treatment of psoriasis. Biomed Pharmacother 2018,107(7),447-463","journal-title":"Biomed Pharmacother"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0190-9622(85)70188-0","volume":"13","author":"Henseler T.","year":"1985","unstructured":"Henseler T.; Christophers E.; Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985,13(3),450-456","journal-title":"J Am Acad Dermatol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"102364","DOI":"10.1016\/j.jddst.2021.102364","volume":"62","author":"Jyothi S.L.","year":"2021","unstructured":"Jyothi S.L.; Krishna K.L.; Ameena Shirin V.K.; Sankar R.; Pramod K.; Gangadharappa H.V.; Drug delivery systems for the treatment of psoriasis: Current status and prospects. J Drug Deliv Sci Technol 2021,62(12),102364","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.12788\/j.sder.2018.011","volume":"37","author":"Armstrong A.W.","year":"2018","unstructured":"Armstrong A.W.; Gordon K.B.; Wu J.J.; Wu J.J.; Common and not-so-common comorbidities of psoriasis. Semin Cutan Med Surg 2018,37(2S),S48-S51","journal-title":"Semin Cutan Med Surg"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.berh.2006.02.002","volume":"20","author":"FitzGerald O.","year":"2006","unstructured":"FitzGerald O.; Dougados M.; Psoriatic arthritis: One or more diseases? Best Pract Res Clin Rheumatol 2006,20(3),435-450","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"102671","DOI":"10.1016\/j.jddst.2021.102671","volume":"64","author":"Tambe V.S.","year":"2021","unstructured":"Tambe V.S.; Nautiyal A.; Wairkar S.; Topical lipid nanocarriers for management of psoriasis - an overview. J Drug Deliv Sci Technol 2021,64(5),102671","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"573.e1","DOI":"10.1016\/j.jaad.2005.03.046","volume":"53","author":"Gelfand J.M.","year":"2005","unstructured":"Gelfand J.M.; Gladman D.D.; Mease P.J.; Smith N.; Margolis D.J.; Nijsten T.; Stern R.S.; Feldman S.R.; Rolstad T.; Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005,53(4),573.e1-573.e13","journal-title":"J Am Acad Dermatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.mcna.2009.08.003","volume":"93","author":"Levine D.","year":"2009","unstructured":"Levine D.; Gottlieb A.; Evaluation and management of psoriasis: An internist\u2019s guide. Med Clin North Am 2009,93(6),1291-1303","journal-title":"Med Clin North Am"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","volume":"13","author":"Raychaudhuri S.K.","year":"2014","unstructured":"Raychaudhuri S.K.; Maverakis E.; Raychaudhuri S.P.; Diagnosis and classification of psoriasis. Autoimmun Rev 2014,13(4-5),490-495","journal-title":"Autoimmun Rev"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"Griffiths C.E.M.","year":"2021","unstructured":"Griffiths C.E.M.; Armstrong A.W.; Gudjonsson J.E.; Barker J.N.W.N.; Psoriasis. Lancet 2021,397(10281),1301-1315","journal-title":"Lancet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"Rendon A.","year":"2019","unstructured":"Rendon A.; Sch\u00e4kel K.; Psoriasis pathogenesis and treatment. Int J Mol Sci 2019,20(6),1475","journal-title":"Int J Mol Sci"},{"key":"ref=15","author":"Saleh D.","year":"2022","unstructured":"Saleh D.; Tanner L.S.;  Guttate psoriasis Available from:  [Accessed March 27, 2022].2022","journal-title":"Guttate psoriasis"},{"key":"ref=16","unstructured":"Guttate Psoriasis: Overview of Guttate Psoriasis, Pathophysiology of Guttate Psoriasis, Epidemiology of Guttate Psoriasis. Available from:  [Accessed March 27, 2022]."},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"Armstrong A.W.","year":"2020","unstructured":"Armstrong A.W.; Read C.; Pathophysiology, clinical presentation, and treatment of psoriasis. JAMA 2020,323(19),1945-1960","journal-title":"JAMA"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms15382","volume":"8","author":"Tsoi L.C.","year":"2017","unstructured":"Tsoi L.C.; Stuart P.E.; Tian C.; Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nat Commun 2017 2017,8(1),1-8","journal-title":"Nat Commun 2017"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"a015354","DOI":"10.1101\/cshperspect.a015354","volume":"4","author":"Di Meglio P.","year":"2014","unstructured":"Di Meglio P.; Villanova F.; Nestle F.O.; Psoriasis. Cold Spring Harb Perspect Med 2014,4(8),a015354","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/jdv.14386","volume":"31","author":"Navarini A.A.","year":"2017","unstructured":"Navarini A.A.; Burden A.D.; Capon F.; Mrowietz U.; Puig L.; K\u00f6ks S.; Kingo K.; Smith C.; Barker J.N.; European consensus state-ment on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol 2017,31(11),1792-1799","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/PTT.S101232","volume":"6","author":"Liao W.","year":"2016","unstructured":"Liao W.; Singh R.; Lee K.; ucmak, ; Brodsky M.; Atanelov Z.; Farahnik B.; Abrouk M.; Nakamura M.; Hao Zhu T.; Erythrodermic psoriasis: Pathophysiology and current treatment perspectives. Psoriasis 2016,6,93-104","journal-title":"Psoriasis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1752-1947-4-179","volume":"4","author":"Teran C.G.","year":"2010","unstructured":"Teran C.G.; Teran-Escalera C.N.; Balderrama C.; A severe case of erythrodermic psoriasis associated with advanced nail and joint mani-festations: A case report. J Med Case Reports 2010,4(1),179","journal-title":"J Med Case Reports"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaad.2009.05.048","volume":"62","author":"Rosenbach M.","year":"2010","unstructured":"Rosenbach M.; Hsu S.; Korman N.J.; Lebwohl M.G.; Young M.; Bebo B.F.; Van Voorhees A.S.; Treatment of erythrodermic psori-asis: From the medical board of the national psoriasis foundation. J Am Acad Dermatol 2010,62(4),655-662","journal-title":"J Am Acad Dermatol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/PTT.S126281","volume":"7","author":"Haneke E.","year":"2017","unstructured":"Haneke E.; Nail psoriasis: Clinical features, pathogenesis, differential diagnoses, and management. Psoriasis 2017,7,51-63","journal-title":"Psoriasis"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10227-002-0143-0","volume":"7","author":"Salomon J.","year":"2003","unstructured":"Salomon J.; Szepietowski J.C.; Proniewicz A.; Psoriatic nails: A prospective clinical study. J Cutan Med Surg 2003,7(4),317-321","journal-title":"J Cutan Med Surg"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5114\/reum.2017.68912","volume":"3","author":"Sobolewski P.","year":"2017","unstructured":"Sobolewski P.; Walecka I.; Dopytalska K.; Nail involvement in psoriatic arthritis. Reumatologia 2017,3(3),131-135","journal-title":"Reumatologia"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2147\/CCID.S189000","volume":"12","author":"Micali G.","year":"2020","unstructured":"Micali G.; Verz\u00ec A.E.; Giuffrida G.; Panebianco E.; Musumeci M.L.; Lacarrubba F.; Inverse psoriasis: From diagnosis to current treat-ment options. Clin Cosmet Investig Dermatol 2020,12,953-959","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1080\/09546634.2019.1620912","volume":"31","author":"Reynolds K.A.","year":"2020","unstructured":"Reynolds K.A.; Pithadia D.J.; Lee E.B.; Wu J.J.; Treatments for inverse psoriasis: A systematic review. J Dermatolog Treat 2020,31(8),786-793","journal-title":"J Dermatolog Treat"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"e384","DOI":"10.1111\/jdv.12004","volume":"27","author":"Janagond A.B.","year":"2013","unstructured":"Janagond A.B.; Kanwar A.J.; Handa S.; Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: A prospective, randomized study. J Eur Acad Dermatol Venereol 2013,27(3),e384-e389","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=30","doi-asserted-by":"publisher","author":"Krulig E.","unstructured":"Krulig E.; Gordon K.B.; Palmoplantar psoriasis. Mild-to-moderate psoriasis 183-195.","DOI":"10.3109\/9781841847153.013"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1046\/j.1525-1470.2000.01746.x","volume":"17","author":"Raychaudhuri S.P.","year":"2000","unstructured":"Raychaudhuri S.P.; Gross J.; A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol 2000,17(3),174-178","journal-title":"Pediatr Dermatol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40257-016-0222-4","volume":"18","author":"Wang T.S.","year":"2017","unstructured":"Wang T.S.; Tsai T.F.; Managing scalp psoriasis: An evidence-based review. Am J Clin Dermatol 2017,18(1),17-43","journal-title":"Am J Clin Dermatol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/bs.acc.2020.04.004","volume":"100","author":"de Alcantara C.C.","year":"2021","unstructured":"de Alcantara C.C.; Reiche E.M.V.; Sim\u00e3o A.N.C.; Cytokines in psoriasis. Adv Clin Chem 2021,100,171-204","journal-title":"Adv Clin Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/B978-0-12-813939-4.00005-X","author":"Cacabelos R.","year":"2019","unstructured":"Cacabelos R.;  Pathoepigenetics: The role of epigenetic biomarkers in disease pathogenesis Pharmacoepigenetics 2019,139-189","journal-title":"Pathoepigenetics: The role of epigenetic biomarkers in disease pathogenesis Pharmacoepigenetics"},{"key":"ref=35","first-page":"496","volume":"361","author":"Frank Nestle P.O.","year":"2009","unstructured":"Frank Nestle P.O.; Kaplan D.H.; Barker ;  J Psoriasis 2009,361(5),496-509","journal-title":"J Psoriasis"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","volume":"34","author":"Lowes M.A.","year":"2013","unstructured":"Lowes M.A.; Russell C.B.; Martin D.A.; Towne J.E.; Krueger J.G.; The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratino-cyte responses. Trends Immunol 2013,34(4),174-181","journal-title":"Trends Immunol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.3389\/fimmu.2018.01549","volume":"9","author":"Albanesi C.","year":"2018","unstructured":"Albanesi C.; Madonna S.; Gisondi P.; Girolomoni G.; The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis. Front Immunol 2018,9(JUL),1549","journal-title":"Front Immunol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3389\/fonc.2019.01370","volume":"9","author":"Quintero-Fabi\u00e1n S.","year":"2019","unstructured":"Quintero-Fabi\u00e1n S.; Arreola R.; Becerril-Villanueva E.; Torres-Romero J.C.; Arana-Arg\u00e1ez V.; Lara-Riegos J.; Ram\u00edrez-Camacho M.A.; Alvarez-S\u00e1nchez M.E.; Role of matrix metalloproteinases in angiogenesis and cancer. Front Oncol 2019,9,1370","journal-title":"Front Oncol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2133.1999.140S54001.x","volume":"54","author":"Ortonne J.P.","year":"1999","unstructured":"Ortonne J.P.; Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol 1999,54(S140),1-7","journal-title":"Br J Dermatol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"699900","DOI":"10.3389\/fimmu.2021.699900","volume":"12","author":"Zeng J.","year":"2021","unstructured":"Zeng J.; Zhang Y.; Zhang H.; Zhang Y.; Gao L.; Tong X.; Xie Y.; Hu Q.; Chen C.; Ding S.; Lu J.; RPL22 overexpression promotes psoriasis-like lesion by inducing keratinocytes abnormal biological behavior. Front Immunol 2021,12,699900","journal-title":"Front Immunol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.gene.6364351","volume":"8","author":"Liu Y.","year":"2007","unstructured":"Liu Y.; Krueger J.G.; Bowcock A.M.; Psoriasis: Genetic associations and immune system changes. Genes Immun 2007,8(1),1-12","journal-title":"Genes Immun"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/1523-1747.ep12344044","volume":"106","author":"Hodak E.","year":"1996","unstructured":"Hodak E.; Gottlieb A.B.; Anzilotti M.; Krueger J.G.; The insulin-like growth factor 1 receptor is expressed by epithelial cells with prolif-erative potential in human epidermis and skin appendages: Correlation of increased expression with epidermal hyperplasia. J Invest Dermatol 1996,106(3),564-570","journal-title":"J Invest Dermatol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1084\/jem.175.4.1081","volume":"175","author":"Krane J.F.","year":"1992","unstructured":"Krane J.F.; Gottlieb A.B.; Carter D.M.; Krueger J.G.; The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor. J Exp Med 1992,175(4),1081-1090","journal-title":"J Exp Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0002-9440(10)64715-3","volume":"156","author":"Detmar M.","year":"2000","unstructured":"Detmar M.; Velasco P.; Richard L.; Claffey K.P.; Streit M.; Riccardi L.; Skobe M.; Brown L.F.; Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas. Am J Pathol 2000,156(1),159-167","journal-title":"Am J Pathol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/nature05663","volume":"445","author":"Lowes M.A.","year":"2007","unstructured":"Lowes M.A.; Bowcock A.M.; Krueger J.G.; Pathogenesis and therapy of psoriasis. Nature 2007,445(7130),866-873","journal-title":"Nature"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1242\/dmm.009092","volume":"5","author":"Johnson-Huang L.M.","year":"2012","unstructured":"Johnson-Huang L.M.; Lowes M.A.; Krueger J.G.; Putting together the psoriasis puzzle: An update on developing targeted therapies. Dis Model Mech 2012,5(4),423-433","journal-title":"Dis Model Mech"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1172\/JCI118989","volume":"98","author":"Wrone-Smith T.","year":"1996","unstructured":"Wrone-Smith T.; Nickoloff B.J.; Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996,98(8),1878-1887","journal-title":"J Clin Invest"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/cmi.2012.15","volume":"9","author":"Cai Y","year":"2012","unstructured":"Cai Y; Fleming C; Yan J.; New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol 2012 2012,9(4),302-309","journal-title":"Cell Mol Immunol 2012"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1046\/j.0022-202x.2001.01548.x","volume":"117","author":"Norris D.A.","year":"2001","unstructured":"Norris D.A.; Kotzin B.L.; Lin W-J.; Achziger M.; Tomkinson B.; Oligoclonal expansion of intraepidermal T cells in psoriasis skin le-sions. J Invest Dermatol 2001,117(6),1546-1553","journal-title":"J Invest Dermatol"},{"key":"ref=50","first-page":"365","volume":"10","author":"Behrendt C.","unstructured":"Behrendt C.; Gollnick H.; Bonnekoh B.; Up-regulated perforin expression of CD8+ blood lymphocytes in generalized nonanaphylactic drug eruptions and exacerbated psoriasis. Eur J Dermatol Available from:  [Accessed March 29, 2022].,10(5),365-369","journal-title":"Eur J Dermatol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"113899","DOI":"10.1016\/j.addr.2021.113899","volume":"176","author":"Dur\u00e1n-Lobato M.","year":"2021","unstructured":"Dur\u00e1n-Lobato M.; L\u00f3pez-Est\u00e9vez A.M.; Cordeiro A.S.; Dacoba T.G.; Crecente-Campo J.; Torres D.; Alonso M.J.; Nanotechnologies for the delivery of biologicals: Historical perspective and current landscape. Adv Drug Deliv Rev 2021,176,113899","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrd4363","volume":"13","author":"Mitragotri S.","year":"2014","unstructured":"Mitragotri S.; Burke P.A.; Langer R.; Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strate-gies. Nat Rev Drug Discov 2014,13(9),655-672","journal-title":"Nat Rev Drug Discov"},{"key":"ref=53","doi-asserted-by":"publisher","DOI":"10.1039\/9781849735292-00003","author":"Alonso M.J.","unstructured":"Alonso M.J.; Couvreur P.;  In: Historical view of the design and development of nanocarriers for overcoming biological barriers Royal Society Of Chemistry, pp.3-36.","journal-title":"In: Historical view of the design and development of nanocarriers for overcoming biological barriers"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/B978-0-12-817909-3.00015-7","author":"Mishra D.K.","year":"1773","unstructured":"Mishra D.K.; Pandey V.; Maheshwari R.; Ghode P.; Tekade, RK Basic Fundam. Drug Deliv 1773,595-650","journal-title":"Drug Deliv"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/jat.1773","volume":"32","author":"Chiang A.","year":"2012","unstructured":"Chiang A.; Tudela E.; Maibach H.I.; Percutaneous absorption in diseased skin: An overview. J Appl Toxicol 2012,32(8),537-563","journal-title":"J Appl Toxicol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1517\/17425247.2015.982088","volume":"12","author":"Rahman M.","year":"2015","unstructured":"Rahman M.; Akhter S.; Ahmad J.; Ahmad M.Z.; Beg S.; Ahmad F.J.; Nanomedicine-based drug targeting for psoriasis: Potentials and emerging trends in nanoscale pharmacotherapy. Expert Opin Drug Deliv 2015,12(4),635-652","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1248\/bpb.29.1790","volume":"29","author":"Rawat M.","year":"2006","unstructured":"Rawat M.; Singh D.; Saraf S.; Saraf S.; Nanocarriers: Promising vehicle for bioactive drugs. Biol Pharm Bull 2006,29(9),1790-1798","journal-title":"Biol Pharm Bull"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3109\/21691401.2014.883401","volume":"43","author":"Singh D.","year":"2015","unstructured":"Singh D.; Pradhan M.; Nag M.; Singh M.R.; Vesicular system: Versatile carrier for transdermal delivery of bioactives. Artif Cells Nanomed Biotechnol 2015,43(4),282-290","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jconrel.2015.10.049","volume":"240","author":"Goyal R.","year":"2016","unstructured":"Goyal R.; Macri L.K.; Kaplan H.M.; Kohn J.; Nanoparticles and nanofibers for topical drug delivery. J Control Release 2016,240,77-92","journal-title":"J Control Release"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1208\/s12248-015-9814-9","volume":"17","author":"Wen H.","year":"2015","unstructured":"Wen H.; Jung H.; Li X.; Drug delivery approaches in addressing clinical pharmacology-related issues: Opportunities and challenges. AAPS J 2015,17(6),1327-1340","journal-title":"AAPS J"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2174\/156720112800389124","volume":"9","author":"Rawat Singh M.","year":"2012","unstructured":"Rawat Singh M.; Pradhan K.; Singh D.; Lipid matrix systems with emphasis on lipid microspheres: Potent carriers for transcutaneous delivery of bioactives. Curr Drug Deliv 2012,9(3),243-254","journal-title":"Curr Drug Deliv"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/jps.2600830902","volume":"83","author":"Touitou E.","year":"1994","unstructured":"Touitou E.; Junginger H.E.; Weiner N.D.; Nagai T.; Mezei M.; Liposomes as carriers for topical and transdermal delivery. J Pharm Sci 1994,83(9),1189-1203","journal-title":"J Pharm Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.smim.2017.09.007","volume":"34","author":"Dacoba T.G.","year":"2017","unstructured":"Dacoba T.G.; Olivera A.; Torres D.; Crecente-Campo J.; Alonso M.J.; Modulating the immune system through nanotechnology. Semin Immunol 2017,34,78-102","journal-title":"Semin Immunol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/22123911MTAziOTU84","volume":"15","author":"Bakshi H.","year":"2020","unstructured":"Bakshi H.; Nagpal M.; Singh M.; Dhingra G.A.; Aggarwal G.; Treatment of psoriasis: A comprehensive review of entire therapies. Curr Drug Saf 2020,15(2),82-104","journal-title":"Curr Drug Saf"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"Patra J.K.","year":"2018","unstructured":"Patra J.K.; Das G.; Fraceto L.F.; Campos E.V.R.; Rodriguez-Torres M.P.; Acosta-Torres L.S.; Diaz-Torres L.A.; Grillo R.; Swamy M.K.; Sharma S.; Habtemariam S.; Shin H-S.; Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology 2018,16(1),71","journal-title":"J Nanobiotechnology"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/2230-973X.96920","volume":"2","author":"Tiwari G.","year":"2012","unstructured":"Tiwari G.; Tiwari R.; Bannerjee S.K.; Bhati L.; Pandey S.; Pandey P.; Sriwastawa B.; Drug delivery systems: An updated review. Int J Pharm Investig 2012,2(1),2-11","journal-title":"Int J Pharm Investig"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"105638","DOI":"10.1016\/j.ejps.2020.105638","volume":"158","author":"G\u00fcng\u00f6r S.","year":"2021","unstructured":"G\u00fcng\u00f6r S.; Kahraman E.; Nanocarriers mediated cutaneous drug delivery. Eur J Pharm Sci 2021,158,105638","journal-title":"Eur J Pharm Sci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3390\/nano9040638","volume":"9","author":"Garc\u00eda-Pinel B.","year":"2019","unstructured":"Garc\u00eda-Pinel B.; Porras-Alcal\u00e1 C.; Ortega-Rodr\u00edguez A.; Sarabia F.; Prados J.; Melguizo C.; L\u00f3pez-Romero J.M.; Lipid-based nanopar-ticles: Application and recent advances in cancer treatment. Nanomaterials 2019,9(4),638","journal-title":"Nanomaterials"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.3390\/pharmaceutics13111978","volume":"13","author":"Singh S.","year":"2021","unstructured":"Singh S.; Sharma N.; Behl T.; Sarkar B.C.; Saha H.R.; Garg K.; Singh S.K.; Arora S.; Amran M.S.; Abdellatif A.A.H.; Bilgrami A.L.; Ashraf G.M.; Rahman M.S.; Promising strategies of colloidal drug delivery-based approaches in psoriasis management. Pharmaceutics 2021,13(11),1978","journal-title":"Pharmaceutics"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"111262","DOI":"10.1016\/j.colsurfb.2020.111262","volume":"195","author":"Chacko I.A.","year":"2020","unstructured":"Chacko I.A.; Ghate V.M.; Dsouza L.; Lewis S.A.; Lipid vesicles: A versatile drug delivery platform for dermal and transdermal applica-tions. Colloids Surf B Biointerfaces 2020,195,111262","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.xphs.2016.10.001","volume":"106","author":"Jain S.","year":"2017","unstructured":"Jain S.; Patel N.; Shah M.K.; Khatri P.; Vora N.; Recent advances in lipid-based vesicles and particulate carriers for topical and trans-dermal application. J Pharm Sci 2017,106(2),423-445","journal-title":"J Pharm Sci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.2174\/1381612825666190903155321","volume":"25","author":"Rajpoot K.","year":"2019","unstructured":"Rajpoot K.; Solid lipid nanoparticles: A promising nanomaterial in drug delivery. Curr Pharm Des 2019,25(37),3943-3959","journal-title":"Curr Pharm Des"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1248\/yakushi.128.269","volume":"128","author":"Rawat M.","year":"2008","unstructured":"Rawat M.; Singh D.; Saraf S.; Saraf S.; Lipid carriers: A versatile delivery vehicle for proteins and peptides. Yakugaku Zasshi 2008,128(2),269-280","journal-title":"Yakugaku Zasshi"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3109\/1061186X.2012.716845","volume":"20","author":"Iqbal M.A.","year":"2012","unstructured":"Iqbal M.A.; Md S.; Sahni J.K.; Baboota S.; Dang S.; Ali J.; Nanostructured lipid carriers system: Recent advances in drug delivery. J Drug Target 2012,20(10),813-830","journal-title":"J Drug Target"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"201","DOI":"10.37022\/WJCMPR.2020.2222","volume":"2","author":"Azad S.","year":"2020","unstructured":"Azad S.; Meeravali S.N.; Babu P.C.; Kumar K.R.; Naik V.; Vasu N.; Micro emulsions: An overview and pharmaceutical applications. World Journal of Current Medical and Pharmaceutical Research 2020,2(2),201-205","journal-title":"World Journal of Current Medical and Pharmaceutical Research"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s13346-015-0274-7","volume":"6","author":"Aghabegi Moghanjoughi A.","year":"2016","unstructured":"Aghabegi Moghanjoughi A.; Khoshnevis D.; Zarrabi A.; A concise review on smart polymers for controlled drug release. Drug Deliv Transl Res 2016,6(3),333-340","journal-title":"Drug Deliv Transl Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jconrel.2020.12.027","volume":"330","author":"Araste F.","year":"2021","unstructured":"Araste F.; Aliabadi A.; Abnous K.; Taghdisi S.M.; Ramezani M.; Alibolandi M.; Self-assembled polymeric vesicles: Focus on poly-mersomes in cancer treatment. J Control Release 2021,330,502-528","journal-title":"J Control Release"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"e01343","DOI":"10.1016\/j.heliyon.2019.e01343","volume":"5","author":"Tripathi P.K.","year":"2019","unstructured":"Tripathi P.K.; Gorain B.; Choudhury H.; Srivastava A.; Kesharwani P.; Dendrimer entrapped microsponge gel of dithranol for effective topical treatment. Heliyon 2019,5(3),e01343","journal-title":"Heliyon"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0168-3659(99)00247-3","volume":"65","author":"Carino G.P.","year":"2000","unstructured":"Carino G.P.; Jacob J.S.; Mathiowitz E.; Nanosphere based oral insulin delivery. J Control Release 2000,65(1-2),261-269","journal-title":"J Control Release"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ejpb.2006.11.009","volume":"65","author":"Letchford K.","year":"2007","unstructured":"Letchford K.; Burt H.; A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 2007,65(3),259-269","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2174\/1872211313666190123153711","volume":"12","author":"Erdo\u011far N.","year":"2019","unstructured":"Erdo\u011far N.; Akk\u0131n S.; Bilensoy E.; Nanocapsules for drug delivery: An updated review of the last decade. Recent Pat Drug Deliv Formul 2019,12(4),252-266","journal-title":"Recent Pat Drug Deliv Formul"},{"key":"ref=82","first-page":"381","volume":"44","author":"Daraee H.","year":"2014","unstructured":"Daraee H.; Etemadi A.; Kouhi M.; Alimirzalu S.; Akbarzadeh A.; Application of liposomes in medicine and drug delivery. An. Interna-tional J Available from:  [Accessed April 2, 2022].2014,44(1),381-391","journal-title":"Interna-tional J"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2147\/IJN.S68861","volume":"10","author":"Bozzuto G.","year":"2015","unstructured":"Bozzuto G.; Molinari A.; Liposomes as nanomedical devices. Int J Nanomedicine 2015,10,975-999","journal-title":"Int J Nanomedicine"},{"key":"ref=84","first-page":"381","volume":"44","author":"Daraee H.","year":"2014","unstructured":"Daraee H.; Etemadi A.; Kouhi M.; Alimirzalu S.; Akbarzadeh A.; Application of liposomes in medicine and drug delivery. An Int J 2014,44(1),381-391","journal-title":"An Int J"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1556-276X-8-102","volume":"8","author":"Akbarzadeh A.","year":"2013","unstructured":"Akbarzadeh A.; Rezaei-Sadabady R.; Davaran S.; Joo S.W.; Zarghami N.; Hanifehpour Y.; Samiei M.; Kouhi M.; Nejati-Koshki K.; Liposome: Classification, preparation, and applications. Nanoscale Res Lett 2013,8(1),102","journal-title":"Nanoscale Res Lett"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/B978-0-12-821712-2.00002-5","author":"Shaw T.K.","year":"2021","unstructured":"Shaw T.K.; Khamkat P.; Ghosh A.; Ghosh M.K.;  Multifunct Theranostic Nanomedicines Cancer 2021,251-273","journal-title":"Multifunct Theranostic Nanomedicines Cancer"},{"key":"ref=87","unstructured":"Liposomes in drug-delivery. (A) Unilamellar vesicles of increasing. Download Scientific Diagram. Available from:  [Accessed April 2, 2022]."},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/IJN.S26766","volume":"7","author":"Yeh M.K.","year":"2011","unstructured":"Yeh M.K.; Hsin I.C.; Ming Y.C.; Clinical development of liposome based drugs: Formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 2011,7,49-60","journal-title":"Int J Nanomedicine"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"wnan.1450","DOI":"10.1002\/wnan.1450","volume":"9","author":"Lee Y.","year":"2017","unstructured":"Lee Y.; Thompson D.H.; Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2017,9(5),wnan.1450","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"ref=90","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-47862-2_2","author":"Siler-Marinkovic S.","unstructured":"Siler-Marinkovic S.;  Percutaneous Penetration Enhanc Chem Methods Penetration Enhanc Nanocarriers Springer, Berlin, Heidelberg, pp. 15-38","journal-title":"Percutaneous Penetration Enhanc Chem Methods Penetration Enhanc Nanocarriers"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"9743","DOI":"10.3390\/ijms22189743","volume":"22","author":"Souto E.B.","year":"2021","unstructured":"Souto E.B.; Macedo A.S.; Dias-Ferreira J.; Cano A.; Zieli\u0144ska A.; Matos C.M.; Elastic and ultradeformable liposomes for transdermal delivery of active pharmaceutical ingredients (APIs). Int J Mol Sci 2021,22(18),9743","journal-title":"Int J Mol Sci"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"646554","DOI":"10.3389\/fbioe.2021.646554","volume":"9","author":"Yu Y.Q.","year":"2021","unstructured":"Yu Y.Q.; Yang X.; Wu X.F.; Fan Y.B.; Enhancing permeation of drug molecules across the skin via delivery in nanocarriers: Novel strategies for effective transdermal applications. Front Bioeng Biotechnol 2021,9,646554","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1124\/pr.115.012070","volume":"68","author":"Yingchoncharoen P.","year":"2016","unstructured":"Yingchoncharoen P.; Kalinowski D.S.; Richardson D.R.; Lipid-based drug delivery systems in cancer therapy: What is available and what is yet to come. Pharmacol Rev 2016,68(3),701-787","journal-title":"Pharmacol Rev"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ejpb.2012.04.005","volume":"81","author":"Knudsen N.\u00d8.","year":"2012","unstructured":"Knudsen N.\u00d8.; R\u00f8nholt S.; Salte R.D.; Jorgensen L.; Thormann T.; Basse L.H.; Hansen J.; Frokjaer S.; Foged C.; Calcipotriol delivery into the skin with PEGylated liposomes. Eur J Pharm Biopharm 2012,81(3),532-539","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"118623","DOI":"10.1016\/j.ijpharm.2019.118623","volume":"569","author":"Bahramizadeh M.","year":"2019","unstructured":"Bahramizadeh M.; Bahramizadeh M.; Kiafar B.; Jafarian A.H.; Nikpoor A.R.; Hatamipour M.; Esmaily H.; Rezaeemehr Z.; Golmo-hammadzadeh S.; Moosavian S.A.; Jafari M.R.; Development, characterization and evaluation of topical methotrexate-entrapped deform-able liposome on imiquimod-induced psoriasis in a mouse model. Int J Pharm 2019,569(5),118623","journal-title":"Int J Pharm"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijpharm.2003.10.006","volume":"270","author":"Trotta M.","year":"2004","unstructured":"Trotta M.; Peira E.; Carlotti M.E.; Gallarate M.; Deformable liposomes for dermal administration of methotrexate. Int J Pharm 2004,270(1-2),119-125","journal-title":"Int J Pharm"},{"key":"ref=97","first-page":"529","volume":"29","author":"Agarwal R","year":"2002","unstructured":"Agarwal R; Saraswat A; Kaur I.A.; 2002 lipossomas psor\u00edase. 2002,29(8),529-532"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.2042-7158.1982.tb04767.x","volume":"34","author":"Mezei M.","year":"2011","unstructured":"Mezei M.; Gulasekharam V.; Liposomes-A selective drug delivery system for the topical route of administration: Gel dosage form. J Pharm Pharmacol 2011,34(7),473-474","journal-title":"J Pharm Pharmacol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3109\/10717544.2015.1110845","volume":"23","author":"Wadhwa S.","year":"2016","unstructured":"Wadhwa S.; Singh B.; Sharma G.; Raza K.; Katare O.P.; Liposomal fusidic acid as a potential delivery system: A new paradigm in the treatment of chronic plaque psoriasis. Drug Deliv 2016,23(4),1204-1213","journal-title":"Drug Deliv"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/08982104.2019.1593449","volume":"30","author":"Walunj M.","year":"2020","unstructured":"Walunj M.; Doppalapudi S.; Bulbake U.; Khan W.; Preparation, characterization, and in vivo evaluation of cyclosporine cationic lipo-somes for the treatment of psoriasis. J Liposome Res 2020,30(1),68-79","journal-title":"J Liposome Res"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ejps.2016.10.025","volume":"96","author":"Doppalapudi S.","year":"2017","unstructured":"Doppalapudi S.; Jain A.; Chopra D.K.; Khan W.; Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis. Eur J Pharm Sci 2017,96,515-529","journal-title":"Eur J Pharm Sci"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.24966\/PPP-5649\/100005","volume":"1","author":"Cavaco-Paulo A.","year":"2017","unstructured":"Cavaco-Paulo A.; Development of liposomes-in-hydrogel formulations containing betamethasone for topical therapy. Cytokines. Their Relation with Mineral Dust Induced Diseases 2017,1(1),1-8","journal-title":"Their Relation with Mineral Dust Induced Diseases"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12951-020-00635-0","volume":"18","author":"Wang W.","year":"2020","unstructured":"Wang W.; Shu G.; Lu K.; Xu X.; Sun M.; Qi J.; Huang Q.; Tan W.; Du Y.; Flexible liposomal gel dual-loaded with all-trans retinoic acid and betamethasone for enhanced therapeutic efficiency of psoriasis. J Nanobiotechnology 2020,18(1),80","journal-title":"J Nanobiotechnology"},{"key":"ref=104","first-page":"252","volume":"7","author":"Bhatia A.","year":"2004","unstructured":"Bhatia A.; Kumar R.; Katare O.P.; Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation. J Pharm Sci Available from:  [Accessed April 3,2022].2004,7(2),252-259","journal-title":"J Pharm Sci"},{"key":"ref=105","unstructured":"Topical Application of Yolk Lecithin Liposomes Reinforces Skin Barrier Function Against Chemical Agents Such as Psoriasisinducing IMQ and Alleviates Disease Phenotype. Available from:  [Accessed April 3, 2022]."},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijpharm.2019.03.042","volume":"562","author":"Jain S.","year":"2019","unstructured":"Jain S.; Addan R.; Kushwah V.; Harde H.; Mahajan R.R.; Comparative assessment of efficacy and safety potential of multifarious lipid based Tacrolimus loaded nanoformulations. Int J Pharm 2019,562(562),96-104","journal-title":"Int J Pharm"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/21691401.2014.984301","volume":"44","author":"Gupta R.","year":"2014","unstructured":"Gupta R.; Gupta M.; Mangal S.; Agrawal U.; Vyas S.P.; Capsaicin-loaded vesicular systems designed for enhancing localized delivery for psoriasis therapy. Artif Cells Nanomed Biotechnol 2014,44(3),1-10","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=108","first-page":"278","volume":"63","author":"Kim W.B.","year":"2017","unstructured":"Kim W.B.; Jerome D.; Yeung J.; Diagnosis and management of psoriasis. Can Fam Physician 2017,63(4),278","journal-title":"Can Fam Physician"},{"key":"ref=109","first-page":"11","volume":"61","author":"Firouzi P.T.","year":"1998","unstructured":"Firouzi P.T.; Krueger G.G.; Efficacy and safety of treatment modalities for psoriasis. Cutis Available from:  [Accessed April 3, 2022]. 1998,61(2 suppl),11-21","journal-title":"Cutis"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5114\/reum.2018.80718","volume":"56","author":"Dopytalska K.","year":"2018","unstructured":"Dopytalska K.; Sobolewski P.; B\u0142aszczak A.; Szyma\u0144ska E.; Walecka I.; Psoriasis in special localizations. Reumatologia 2018,56(6),392-398","journal-title":"Reumatologia"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"559","DOI":"10.5021\/ad.2017.29.5.559","volume":"29","author":"Choi J.W.","year":"2017","unstructured":"Choi J.W.; Kim B.R.; Youn S.W.; Adherence to topical therapies for the treatment of psoriasis: Surveys of physicians and patients. Ann Dermatol 2017,29(5),559-564","journal-title":"Ann Dermatol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2310\/7750.2012.11124","volume":"17","author":"Wong T.","year":"2013","unstructured":"Wong T.; Hsu L.; Liao W.; Phototherapy in psoriasis: A review of mechanisms of action. J Cutan Med Surg 2013,17(1),6-12","journal-title":"J Cutan Med Surg"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.3390\/ijms18112427","volume":"18","author":"Gisondi P.","year":"2017","unstructured":"Gisondi P.; Girolomoni G.; Girolomoni G.; Treatment approaches to moderate to severe psoriasis. Int J Mol Sci 2017,18(11),2427","journal-title":"Int J Mol Sci"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0068-3","volume":"4","author":"Singh A.P.","year":"2019","unstructured":"Singh A.P.; Biswas A.; Shukla A.; Maiti P.; Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct Target Ther 2019,4(1),1-21","journal-title":"Signal Transduct Target Ther"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"Patra J.K.","year":"2018","unstructured":"Patra J.K.; Das G.; Fraceto L.F.; Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnol 2018,16(1),1-33","journal-title":"J Nanobiotechnol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"101899","DOI":"10.1016\/j.jddst.2020.101899","volume":"59","author":"Chaturvedi S.","year":"2020","unstructured":"Chaturvedi S.; Garg A.; Verma A.; Nano lipid based carriers for lymphatic voyage of anti-cancer drugs: An insight into the in-vitro, ex-vivo, in-situ and in-vivo study models. J Drug Deliv Sci Technol 2020,59(101899),101899","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2174\/1389450122666210824141044","volume":"23","author":"Garg A.","year":"2022","unstructured":"Garg A.; Chaturvedi S.; A comprehensive review on chrysin: Emphasis on molecular targets, pharmacological actions and bio-pharmaceutical aspects. Curr Drug Targets 2022,23(4),420-436","journal-title":"Curr Drug Targets"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"129936","DOI":"10.1016\/j.bbagen.2021.129936","volume":"1865","author":"Rizwanullah M.","year":"2021","unstructured":"Rizwanullah M.; Ahmad M.Z.; Garg A.; Ahmad J.; Advancement in design of nanostructured lipid carriers for cancer targeting and theranostic application. Biochim Biophys Acta, Gen Subj 2021,1865(9),129936","journal-title":"Biochim Biophys Acta, Gen Subj"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2174\/2211738510666220428133532","volume":"10","author":"Rahman M.A.","year":"2022","unstructured":"Rahman M.A.; Shakeel K.; Ahmad F.J.; Harwansh R.K.; \u03b2-Artemether and lumefantrine dual drug loaded lipid nanoparticles: Physico-chemical characterization, pharmacokinetic evaluation and biodistribution study. Pharm Nanotechnol 2022,10(3),210-219","journal-title":"Pharm Nanotechnol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00403-011-1166-4","volume":"303","author":"Pierre M.B.R.","year":"2011","unstructured":"Pierre M.B.R.; dos Santos Miranda Costa I.; Liposomal systems as drug delivery vehicles for dermal and transdermal applications. Arch Dermatol Res 2011,303(9),607-621","journal-title":"Arch Dermatol Res"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.3390\/ijms18122514","volume":"18","author":"Boche\u0144ska K.","year":"2017","unstructured":"Boche\u0144ska K.; Smoli\u0144ska E.; Moskot M.; Jak\u00f3bkiewicz-Banecka J.; Gabig-Cimi\u0144ska M.; Models in the research process of psoriasis. Int J Mol Sci 2017,18(12),2514","journal-title":"Int J Mol Sci"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201024666221213144228","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/211914\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201024666221213144228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T07:03:34Z","timestamp":1690182214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/211914\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":121,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201024666221213144228","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}